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Deficient histone H3 propionylation by BRPF1-KAT6 
complexes in neurodevelopmental disorders and cancer
Kezhi Yan1,2, Justine Rousseau3, Keren Machol4,5, Laura A. Cross6, Katherine E. Agre7,  
Cynthia Forster Gibson8, Anne Goverde9, Kendra L. Engleman6, Hannah Verdin10, 
Elfride De Baere10, Lorraine Potocki4,5, Dihong Zhou6, Maxime Cadieux-Dion6, Gary A. Bellus11, 
Monisa D. Wagner12, Rebecca J. Hale7, Natacha Esber13, Alan F. Riley14, Benjamin D. Solomon15, 
Megan T. Cho15, Kirsty McWalter15, Roy Eyal16, Meagan K. Hainlen6, Bryce A. Mendelsohn16, 
Hillary M. Porter17, Brendan C. Lanpher7, Andrea M. Lewis4,5, Juliann Savatt12, 
Isabelle Thiffault6,18, Bert Callewaert10, Philippe M. Campeau3*, Xiang-Jiao Yang1,2,19,20*
Lysine acetyltransferase 6A (KAT6A) and its paralog KAT6B form stoichiometric complexes with bromodomain- and 
PHD finger-containing protein 1 (BRPF1) for acetylation of histone H3 at lysine 23 (H3K23). We report that these 
complexes also catalyze H3K23 propionylation in vitro and in vivo. Immunofluorescence microscopy and ATAC-See 
revealed the association of this modification with active chromatin. Brpf1 deletion obliterates the acylation in mouse 
embryos and fibroblasts. Moreover, we identify BRPF1 variants in 12 previously unidentified cases of syndromic 
intellectual disability and demonstrate that these cases and known BRPF1 variants impair H3K23 propionylation. 
Cardiac anomalies are present in a subset of the cases. H3K23 acylation is also impaired by cancer-derived somatic 
BRPF1 mutations. Valproate, vorinostat, propionate and butyrate promote H3K23 acylation. These results reveal the 
dual functionality of BRPF1-KAT6 complexes, shed light on mechanisms underlying related developmental disorders 
and various cancers, and suggest mutation-based therapy for medical conditions with deficient histone acylation. 
INTRODUCTION
Histone modifications such as acetylation, phosphorylation, and 
methylation are critical for epigenetic regulation (1). Mass spectrometry 
has recently identified acetylation-like acylation, including propionylation, 
crotonylation, butyrylation, and succinylation (2, 3). These modifications 
exhibit functional difference from acetylation in vitro and may serve 
as fine-tuning mechanisms in vivo. For example, both acetylation 
and crotonylation are recognized by the bromodomains, plant homeo-
domain-linked (PHD) fingers, and YEATS domains, albeit at different 
specificity and affinity (3–7). Like acetylation, the new acylations 
are reversible, but their responsible enzymes are largely unknown. 
Although some in vitro studies show that acetyltransferases and 
deacetylases also catalyze and reverse the acylations, respectively (2, 3), 
the biological relevance remains unclear. Moreover, it is important 
to elucidate if and how the new acylations are linked to disease.
Lysine acetyltransferase 6A (KAT6A) and KAT6B are paralogous 
acetyltransferases of the MYST (Moz-, Ybf2/Sas3-, Sas2-, and 
Tip60-like domain) family, with similar molecular activities in vitro 
but distinct functions in vivo (8). The other three members are KAT5, 
KAT7, and KAT8 (8). Although they have conserved MYST domains 
for acetyltransferase activity (8, 9), these five enzymes show site 
specificity in vivo. KAT6A and KAT6B govern acetylation of histone 
H3 at lysine 23 (H3K23) (10–12), whereas KAT7 is the major enzyme 
for H3K14 acetylation (13–15) and KAT8 is responsible for H4K16 
acetylation (16–19). This specificity is conferred by multisubunit 
complexes. For example, KAT6A and KAT6B form tetrameric com-
plexes with BRPF1 (bromodomain- and PHD finger–containing 
protein 1) and two other proteins (Fig. 1A) (20, 21). BRPF1, in turn, 
activates KAT6A and KAT6B for H3K23 acetylation (20–22).
As for pathological relevance, KAT6A was identified in 1996 as 
a gene rearranged in leukemia (8, 23). KAT6B was then shown to 
be similarly rearranged in leukemia (8, 23). In 2012 and 2015, they 
were reported to be mutated in individuals with intellectual dis-
ability and neurodevelopmental disorders (24–30). A recent study 
analyzed 76 individuals with KAT6A variants (31), and at least 
210 persons with these variants have enrolled in the KAT6A Foun-
dation. Known cases with KAT6B variants have also exceeded 60 (32). 
We and others have just identified BRPF1 variants in 28 individuals 
with syndromic intellectual disability (12, 33–36). The variants 
cause deficient H3K23 acetylation (12, 33). This site is also propi-
onylated (3), but the enzymes are elusive. Here, we identify BRPF1-
KAT6 complexes as the propionyltransferases in vitro and in vivo, 
demonstrate H3K23 propionylation deficiency resulting from 
germline BRPF1 variants in individuals with neurodevelopmental 
disorders or from somatic mutations in different types of cancer, 
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Fig. 1. BRPF1-KAT6 complexes catalyze H3K23 propionylation in vitro. (A) Molecular architecture of the tetrameric complexes. BRPF1 has two EPC (enhancer of 
polycomb)–like motifs: EPC-I is required for association with the MYST domain of KAT6A or KAT6B, whereas EPC-II is necessary and sufficient for interaction with ING5 
(or the paralog ING4) and MEAF6. The BRPF-specific N-terminal (BN) domain also contributes to the association with the MYST domain. BRPF1 contains the PZP domain, 
bromodomain, and PWWP domain for chromatin association. Unlike its paralogs BRPF2 and BRPF3, BRPF1 has an Sfp1-like C2H2 zinc finger (SZ). NLS, nuclear localization 
signal; H1-like, histone H1–like domain; PZP, PHD–zinc knuckle–PHD; bromo, bromodomain; PWWP, Pro-Trp-Trp-Pro containing domain; SM, serine/methionine-rich 
(8, 23). (B) BRPF1 promotes H3K23 propionylation. KAT6A was expressed in HEK293 cells as a FLAG-tagged fusion protein along with HA-tagged BRPF1, ING5, and MEAF6 
as indicated. Affinity-purified proteins were used for acylation of HeLa oligonucleosomes in the presence of the respective acyl-CoA. Immunoblotting with antibodies 
recognizing histone H3 and its acylated forms was used to detect acylation states as indicated. See fig. S2A for immunoblotting analysis of the soluble extracts. Signals 
detected by the anti-H3K23cr and anti-H3K23bu antibodies need to be interpreted with caution due to cross-reactivity to H3K23ac and/or H3K23pr (see fig. S1B). (C) The 
H3K23 propionyltransferase activity is intrinsic to the MYST domain of KAT6A. Complex preparation and assays were performed as in (B) to compare KAT6A with its 
mutants. Recombinant mononucleosomes were used as substrate. See fig. S2B for immunoblotting analysis of the soluble extracts. Asterisks in (B) and (C) denote degraded 
products; the degradation varies from experiment to experiment. (D) Same as in (B) but ING4 and ING5 were compared. See fig. S2C for immunoblotting analysis of the 
soluble extracts. (E) Comparison of KAT6B fragments. Complex preparation and assays were performed as in (B) with the recombinant mononucleosome substrate, but 
KAT6B fragments were analyzed. Full-length KAT6B was difficult to express (21).
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and explore therapeutic strategies with histone deacetylase (HDAC) 
inhibitors and propionic acid.
RESULTS
Tetrameric BRPF1-KAT6 complexes propionylate  
histone H3K23 in vitro
KAT6A and KAT6B are paralogous and form tetrameric complexes 
with BRPF1, ING4 (or ING5), and MEAF6 (Fig. 1A) (20, 21). To 
investigate whether the complexes propionylate H3K23, we carried 
out histone acylation assays with nucleosomes as the substrates. For 
this, KAT6A was expressed in human embryonic kidney (HEK) 
293 cells as a FLAG-tagged fusion protein along with hemagglutinin 
(HA)–tagged BRPF1, ING5, and MEAF6, according to published 
procedures (12, 21). Soluble extracts were prepared for affinity 
purification on anti-FLAG agarose. After stringent washing with a 
buffer containing 0.6 M KCl, bound proteins were eluted and used 
for acylation of HeLa oligonucleosomes [i.e., digested and purified 
from HeLa cell chromatin (12, 21)] in the presence of acyl–coenzyme A 
(CoA) (e.g., acetyl- and propionyl-CoA for acetylation and propionyl-
ation, respectively; fig. S1A). The purified complexes were confirmed 
by immunoblotting analysis with anti-FLAG and anti-HA antibodies 
(fig. S1A, bottom two panels), whereas affinity-purified antibodies 
specific to histone H3 and its acylated forms were used to detect 
histone H3 or its H3K23 acylation, respectively. The acylation-specific 
antibodies specifically recognized H3K23 (fig. S1A, top five panels). 
Compared to H3K23 acetylation, endogenous H3K23 propionylation 
was low in HEK293 cells (fig. S1B, lanes 1 to 3). Notably, the anti- 
H3K23pr antibody was highly specific (fig. S1B).
As previously reported (12), when acetyl-CoA was used as the 
coenzyme, KAT6A acetylated H3K23 in HeLa oligonucleosomes, and 
BRPF1 stimulated this modification (Fig. 1B, top two panels). When 
propionyl-CoA was used as the coenzyme, KAT6A propionylated 
H3K23, and BRPF1 stimulated this new modification (Fig. 1B, panel 3 
from the top). Mass spectrometry uncovered H3K23 crotonylation 
(cr) and H3K23 butyrylation (bu) (2, 3). We then analyzed these two 
modifications (Fig. 1B, panels 4 and 5 from the top), but the anti-
bodies cross-reacted with H3K23 acetylation and/or propionylation 
(fig. S1B, bottom two panels). Thus, we focused mainly on H3K23 
propionylation for this study.
HeLa oligonucleosomes contain endogenous modifications (Fig. 1B, 
lane 1), so we analyzed the activity of the KAT6A complexes in acylation 
of recombinant mononucleosomes. As with HeLa oligonucleosomes, 
KAT6A acetylated or propionylated H3K23 in recombinant mono-
nucleosomes, and BRPF1 stimulated these modifications (Fig. 1C, 
lanes 1 to 3). Because of no basal acylation in recombinant mono-
nucleosomes (Fig. 1C, lane 1), the activities detected with KAT6A 
and its complexes were much more robust than those observed in 
the same assays with HeLa oligonucleosomes (compare Fig. 1, B and C, 
lanes 1 to 3). The MYST domain (Fig. 1A, bottom) was active in 
catalyzing this modification but less efficient than full-length KAT6A 
(Fig. 1C, lanes 3 and 4), whereas the N-MYST fragment (Fig. 1A, 
bottom) was more efficient than the MYST domain alone (Fig. 1C, 
lanes 4 and 5). To investigate whether the observed activity is in-
trinsic to this domain, we engineered and analyzed the MYST domain 
containing arginine substitution of Lys604, whose equivalent residues 
have been identified as autoacetylation sites essential for acetyl-
transferase activities of other MYST proteins (37). As shown in Fig. 1C 
(lanes 4 and 6), this mutant was inactive in promoting H3K23 
acetylation or propionylation, thereby highlighting the critical 
importance of Lys604 and supporting that the observed activities are 
intrinsic to the MYST domain. Together, these results indicate that 
KAT6A propionylates H3K23 through the MYST domain in vitro.
During the analysis of the soluble extracts, we noticed, as reported 
previously (12), that with full-length KAT6A, BRPF1 promoted the 
expression of ING5 and MEAF6 (fig. S2A), perhaps due to the scaffold 
function of BRPF1 (Fig. 1A). This effect was similar with the N-MYST 
fragment (fig. S2B, lane 5) but much less evident with the MYST 
domain or its K604R mutant (lanes 4 and 6), suggesting that the 
N-terminal domain of KAT6A synergizes with BRPF1 in promoting 
the expression of ING5 and MEAF6.
It was reported previously that ING4 also copurified with KAT6A 
(20). In agreement with this, like ING5, ING4 formed tetrameric 
complex with the MYST domain of KAT6A, BRPF1, and MEAF6 
(Fig. 1D, bottom two panels, and fig. S2C). Moreover, the ING4 com-
plex was as active as the ING5 complex in H3K23 acylation (Fig. 1D, 
top three panels). Thus, ING4 and ING5 form similar H3K23 
propionyltransferase complexes.
KAT6A is paralogous to KAT6B (Fig. 1A), so we investigated 
whether KAT6B also propionylates H3K23. For this, we analyzed two 
fragments containing the MYST domain of KAT6B (Fig. 1A, bottom). 
This MYST domain also efficiently propionylated recombinant mono-
nucleosomes (Fig. 1E, lanes 1 and 2). The N-MYST fragment appeared 
to be more efficient than the MYST domain (Fig. 1E, compare lanes 2 
and 3), indicating that the N-terminal part of KAT6B stimulates the 
enzymatic activity. This is similar to what was observed with the 
N-MYST fragment of KAT6A (Fig. 1C, lanes 4 and 5). As illustrated in 
Fig. 1A, the N-MYST fragment of KAT6A or KAT6B corresponds to the 
portion of leukemic fusion proteins resulting from leukemia-associated 
chromosomal translocations (23, 38). These results suggest that the 
translocations do not affect acyltransferase activity of KAT6A or KAT6B.
Deletion of mouse Brpf1 or Kat6a diminishes H3K23 
propionylation in vivo
We next investigated whether the BRPF1-KAT6 complexes are histone 
H3K23 propionyltransferases in vivo. Deletion of mouse Brpf1 markedly 
reduces H3K23 acetylation (11, 12). By analogy, we hypothesized that 
Brpf1 deletion has similar effects on H3K23 propionylation. To test 
this, we first carried out immunoblotting to detect histone H3 acylation 
in protein extracts from control and Brpf1−/− mouse embryonic fibro-
blasts (MEFs) (39). As previously reported (11, 12), H3K23 acetylation 
was abolished in Brpf1−/− MEFs (Fig. 2A). H3K23 propionylation was 
undetectable in these mutant cells (Fig. 2A). By contrast, acetylation 
or propionylation at H3K9 (or H3K14) was not affected (Fig. 2A). 
The H3K23 propionylation deficiency was also observed in Brpf1−/− 
embryos (Fig. 2B). Moreover, immunofluorescence microscopy 
detected marked reduction of H3K23 propionylation in Brpf1−/− MEFs 
(Fig. 2C). Notably, the H3K23 propionylation level was more robust 
in mouse embryos than various cultured cells (fig. S3A). Thus, BRPF1 
is critical for H3K23 propionylation in MEFs and embryos, supporting 
its relevance in vivo.
Brpf1 deletion also abrogated signals detected by the anti-H3K23cr 
and anti-H3K23bu antibodies in MEFs and embryos (Fig. 2, A and B), 
but this may be, in part, due to cross-reactivity with H3K23ac and 
H3K23pr (fig. S1B). We also analyzed total histone H3 acylation using 
anti-propionyllysine and anti-crotonyllysine antibodies. Both detected 
H3 acylation in wild-type and Brpf1−/− MEF extracts (fig. S3, B and C). 
Coimmunoprecipitation revealed that the anti-propionyllysine antibody 
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Fig. 2. Brpf1 inactivation impairs histone H3K23 acylation in mouse fibroblasts and embryos. (A) Immunoblotting to detect histone H3 acylation in extracts from 
control and Brpf1−/− MEFs. The fibroblasts were prepared from control and tamoxifen-inducible Brpf1 knockout embryos at E15.5 (39). (B) Immunoblotting to detect his-
tone H3 acylation in extracts from wild-type and Brpf1−/− embryos at E10.5. (C) Immunofluorescence microscopic analysis of histone H3 propionylation in control and 
Brpf1−/− MEFs (E13.5). Scale bar, 20 m. (D) Immunoblotting analysis to detect histone H3 acetylation and propionylation in extracts from control and Brpf1−/− MEFs (E13.5) 
cultured in the MEF medium supplemented with or without 10 mM sodium propionate for 24 hours. (E) Histone H3 acylation in extracts from control and Kat6a−/− MEFs. 
The fibroblasts were prepared from control and Kat6a−/− embryos at E13.5. (F) Histone H3 acylation in extracts from wild-type and Kat6a−/− embryos at E13.5. (G) Association 
of H3K23ac and H3K23pr with active chromatin. Soluble extracts from E13.5 wild-type (WT) and Brpf1−/− MEFs (lanes 1 and 2) were used for immunoprecipitation (IP) with 
control immunoglobulin G (IgG) (lanes 3 and 4), anti-H3K23ac antibody (lanes 5 and 6), or anti-H3K23pr antibody (lane 7). Immunoblotting was carried out with the anti-
bodies specific to the histone marks indicated at the right. (H and I) Active chromatin of E13.5 wild-type MEFs was labeled with ATAC-See before immunofluorescence 
microscopy with the anti-H3K23ac (H) or anti-H3K23pr (I) antibody. Scale bars, 20 m.
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recognizes histone H3 (fig. S3D). Thus, BRPF1 is not critical for total 
H3 acylation in vivo.
An interesting question is how H3K23 propionylation is regulated. 
One possibility is through propionyl-CoA. Because propionate CoA- 
transferase converts propionate and acetyl-CoA to propionyl-CoA, 
we treated MEFs with sodium propionate and analyzed the effect on 
H3K23 propionylation. As shown in Fig. 2D (lanes 1 and 2), this treat-
ment enhanced H3K23 propionylation but not acetylation, highlighting 
their differential responses to different environmental conditions. 
The enhancement of propionylation in response to propionate treat-
ment was abolished in Brpf1−/− MEFs (lanes 3 and 4), further supporting 
that Brpf1 is required for H3K23 propionylation in vivo.
As BRPF1 activates KAT6A and KAT6B for H3K23 acylation in vitro 
(Fig. 1), we then examined histone H3 acylation in protein extracts 
from control and Kat6a−/− MEFs. As shown in Fig. 2E, H3K23 
acetylation was reduced to about 30 to 50%, whereas H3K23 pro-
pionylation was barely detectable in Kat6a−/− MEFs (Fig. 2E). 
Moreover, in Kat6a−/− embryos, H3K23 acetylation was not affected, 
whereas H3K23 propionylation was reduced markedly (Fig. 2F). 
Residual H3K23 propionylation in mutant MEFs or embryos is likely 
due to Kat6b. These results support the view that KAT6A contributes 
substantially to H3K23 propionylation in vivo.
To determine functional consequences of H3K23ac and H3K23pr, 
we investigated whether they are associated with active chromatin. 
For this, we performed coimmunoprecipitation using the anti- 
H3K23ac or anti-H3K23pr antibody for immunoblotting with anti-
bodies recognizing active and repressive chromatin marks. The 
anti-H3K23ac and anti-H3K23pr antibodies coimmunoprecipitated 
histone H3K14ac (an active chromatin mark) from wild-type MEF 
extracts (Fig. 2G, top, lanes 1, 3, 5, and 7). The former antibody failed 
to do so with Brpf1−/− MEF extracts (lanes 2, 4, and 6), indicating that 
BRPF1-promoted H3K23 acetylation is required for coimmunopre-
cipitation of histone H3K14ac. In contrast, neither antibody coim-
munoprecipitated histone H3K27me3 (a repressive chromatin mark) 
from either wild-type or mutant MEF extracts (Fig. 2G), support-
ing the association of H3K23ac and H3K23pr with active but not re-
pressive chromatin.
To substantiate the association with active chromatin, we also 
analyzed the subnuclear distribution of the modifications at the 
single- cell level. For this, active chromatin was labeled with ATAC-
See, a recently developed technique to link oligonucleotide-coupled 
fluorophore covalently to active chromatin in situ (40). Then, H3K23 
acylation was detected via fluorescence microscopy. H3K23ac- or 
H3K23pr-specific fluorescence signals were associated with chro-
matin labeled by ATAC-See in wild-type E13.5 (embryonic day 
13.5) MEFs (Fig. 2, H and I). Moreover, similar results were ob-
tained with sections prepared from wild-type mouse embryos (fig. 
S4, A and B). One noticeable difference between these two modifi-
cations was that propionylation, but not acetylation, was strong in 
the cerebrocortical neuroepithelium, highlighting the potential im-
portance of H3K23 propionylation in cerebral development at the 
embryonic stage.
BRPF1 variants in 12 new cases of syndromic  
intellectual disability
Having established the BRPF1-KAT6 complexes as H3K23 propionyl-
transferases in vitro (Fig. 1) and in mice (Fig. 2), we then investigated 
the clinical relevance of these findings. We and others have reported 
28 clinical cases of syndromic intellectual disability due to de novo 
or inherited BRPF1 variants (12, 33–35). We have now identified 12 
previously unreported cases (Fig. 3A and table S1), thus bringing 
the total to 40. These cases are mainly from North America and 
Europe, where exome sequencing has been routinely used for clinical 
diagnosis of rare developmental disorders. As shown in table S1, most 
of the newly identified 12 individuals share key clinical features with 
those reported cases (12, 33), including general developmental delay 
and gross/fine motor delay. Many showed intellectual disability and 
had language delay (table S1). Facial and eye dysmorphisms (e.g., 
blepharophimosis and ptosis) are common clinical features, with some 
individuals having vision problems (Fig. 3B, fig. S4C, and table S1). 
Hand and foot anomalies were also observed (Fig. 3C and table S1). 
Some individuals had ear and mouth anomalies (table S1). Hypotonia 
was observed in five cases (table S1). A subset exhibited electro-
encephalogram (EEG) abnormalities and behavioral issues, including 
attention deficit hyperactivity disorder (table S1). Related to intellectual 
disability and language delay, magnetic resonance imaging (MRI) 
analysis detected brain abnormalities (Fig. 3D and table S1), e.g., 
dysmorphism or thinning of the corpus callosum in individuals P7 
and P12 (table S1). One individual displayed cardiac anomalies (P10; 
table S1). Albeit different, cardiac anomalies were also observed in 
the previously described individual with the Trp315Leufs*26 variant 
(Fig. 3E) (12). Although not universally evaluated in this and the 
previous cohort, cardiac anomalies in these two cases indicate a less 
common clinical finding.
The variant c.227C>T in individual P1 (table S1) was inherited 
from an asymptomatic father, suggesting incomplete genetic pene-
trance. This variant is present in P1’s 1-year-old brother, who has 
not yet undergone developmental assessment (table S1). Despite 
language delay, individual P2 displays typical cognitive functioning 
(table S1). Moreover, the c.883_884del variant in individual P4 was 
inherited from her mother (individual P5), who exhibits few clinical 
features; P4’s intelligence quotient (IQ) is within the normal range 
(table S1). These new findings support variable clinical expressivity. 
Related to this, a new study described three brothers who inherited 
the Gln186* variant from their mother (35). The mother is 61 years 
old, with self-perceived normal cognitive function, whereas her 
three sons are all affected (35). Genetic background and environ-
mental influence may contribute to incomplete penetrance and 
variable expressivity.
In the 12 cases identified here (Fig. 3A and table S1), there are 11 
different BRPF1 variants. One of them is shared by a girl and her 
mother (Fig. 3A, c.883_884del, individuals P4 and P5). Moreover, 
the variant in individual P11 (Fig. 3A, c.2497C>T) is identical to a 
previously described one (33), so there are only 10 new variants. 
Six of them lead to C-terminal truncations expected to inactivate 
BRPF1 (Fig. 3A). For similar truncations, we have established that 
the variant transcripts escape nonsense-mediated mRNA decay (12). 
Some truncation variants, such as Gln96* and Asp187Glyfs*29 
(Fig. 3A), may display poor expression, as we have shown for the 
Glu121Glyfs*2 variant (Fig. 4A) (12). Both Gln96* and Asp187Glyfs*29 
also lack the domains for KAT6A/KAT6B interaction (Fig. 3A). 
Met295Valfs*17 and Thr434Profs*61 contain these domains but 
lack an intact PZP (PHD–zinc knuckle–PHD) domain for nucleosome 
binding (Fig. 3A). This domain is critical for BRPF1 to promote 
nucleosomal H3K23 acetylation by KAT6A (12). Both Glu474Glyfs*3 
and Tyr543Thrfs*6 lack intact ECP-II required for ING5/MEAF6 
binding (Fig. 3A). Thus, the six new truncating variants are likely 
pathogenic.
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Fig. 3. Clinical characteristics of newly identified individuals with BRPF1 variants. (A) Schematic representation of variants identified in 12 newly identified individuals 
with syndromic intellectual disability. See Fig. 1A for domain nomenclature. (B) Facial features of seven individuals with heterozygous BRPF1 mutations. The ages when 
the photos were taken are indicated. See fig. S4C for additional photos. (C) Hand and foot photos of individuals P4 and P5. (D) Brain MRI images of individual P1. 
(E) Echocardiographic image of dilated ascending aorta in a previously reported case (12). Photo credit: The authors confirm that permissions were received to use all 
images, but to protect patient identity, photographer names remain anonymous.
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Among the remaining four new variants (Fig. 3A), three alter 
Pro76, Arg318, and His410, with the fourth generating in-frame 
deletion of Phe1154. These four residues are evolutionarily conserved 
from Drosophila to humans (figs. S5 and S6). His410 is a key zinc- 
chelating residue (figs. S5 and S7A), so His410Arg likely disrupts 
the PZP domain. Phe1154 is an integral part of the trimethyl-histone 
binding pocket of the PWWP (Pro-Trp-Trp-Pro) domain (Fig. 3A 
and fig. S7B) (41, 42), so Phe1154del likely inactivates this domain. 
Pro76 is located at the N-terminal region, whereas Arg318 is within 
the first PHD of the PZP domain (Fig. 3A). The functional impact 
of Pro76Leu and Arg318His is not obvious and thus needs further 
experimental validation.
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Fig. 4. Functional impact of BRPF1 variants associated with neurodevelopmental disorders. (A) Cartoon representation of variants previously identified in 29 indi-
viduals with syndromic intellectual disability (12, 33–36) or autism (43). See Fig. 1A for domain nomenclature. (B) Nucleosomal acylation assays. HeLa oligonucleosomes 
were used for acylation by the affinity-purified wild-type and mutant complexes. The complexes were prepared for assays as in Fig. 1B. See fig. S2D for immunoblotting 
analysis of the soluble extracts. (C) Nucleosomal histone acylation assays. Recombinant mononucleosomes were used for acylation by the affinity-purified wild-type and 
mutant complexes. (D) Assays were carried out similarly as in (C), and the MYST domain of KAT6A was used. See fig. S2E for immunoblotting analysis of the soluble ex-
tracts. (E) Immunoblotting to detect histone H3 acylation in extracts from control and the Pro370Ser LCLs. (F) Immunoblotting to detect histone H3 acylation in protein 
extracts from the control and Arg455* LCLs. (G) Immunoblotting to detect histone H3 acylation in extracts from the control and Arg455* fibroblasts. (H) Assays were 
carried out similarly as in (C), but the Tyr406His variant was analyzed. See fig. S2F for immunoblotting analysis of the soluble extracts.
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Developmental disorder-associated BRPF1 mutations 
diminish H3K23 acylation
Because BRPF1 variants were found to cause H3K23 acetylation 
deficiency (12, 33), we asked whether H3K23 propionylation is also 
impaired (Fig. 3A). To assess this, we expressed and affinity-purified 
tetrameric KAT6A complexes containing wild-type or mutant BRPF1 
proteins for histone acylation assays. As noticed previously (12), 
Gln629Hisfs*34, but not Arg455* or His563Profs*8, promoted 
expression of ING5 and MEAF6 (fig. S2D, lanes 1 to 5). This is be-
cause the latter two do not contain EPC-II (enhancer of polycomb II) 
essential for ING5/MEAF6 binding (Fig. 4A). ING5 and MEAF6 did 
not copurify with these two variants (Fig. 4B, bottom two panels, lanes 4 
and 5, and fig. S2D). Unlike Arg455*, both His563Profs*8 and 
Gln629Hisfs*34 stimulated H3K23 acetylation or propionylation 
by KAT6A (Fig. 4B, top three panels). The observed activity of 
His563Profs*8 suggests that ING5/MEAF6 binding is dispensable 
for BRPF1 to stimulate acylation by KAT6A. As previously reported 
(12), the loss of the PWWP domain in Gln629Hisfs*34 (Fig. 4A) may 
affect histone methylation–based genome targeting in vivo.
We also analyzed the four missense variants (Pro76Leu, Arg318His, 
Pro370Ser, and Cys389Arg). Among them, Pro370Ser is defective for 
stimulating H3K23 acetylation by KAT6A (12). Like this mutant, 
Cys389Arg was also inactive in stimulating H3K23 acetylation (Fig. 4C, 
top two panels). Neither variant stimulated H3K23 propionylation 
by KAT6A (Fig. 4C, middle). As shown in Fig. 4D (bottom two panels) 
and fig. S2E, Arg318His formed a tetrameric complex normally with 
the MYST domain of KAT6A, ING5, and MEAF6, but Thr434Profs*61 
did not interact with ING5 and MEAF6. This is expected as this 
variant lacks EPC-II required for ING5/MEAF6 binding (Fig. 3A). 
Neither Thr434Profs*61 nor Arg318His stimulated H3K23 acetylation 
or propionylation by the MYST domain of KAT6A (Fig. 4D, 
top three panels).
The Pro76Leu variant was normally expressed and promoted the 
expression of ING5 and MEAF6 as wild-type BRPF1 (fig. S7C). 
Moreover, similar to wild-type BRPF1, this variant stimulated H3K23 
acylation by KAT6A (fig. S7D). As Pro76 is located at a serine-rich 
region (fig. S5), this variant may be affected in vivo in terms of regula-
tion by phosphorylation. Clinical features such as macrocephaly also 
make this case stand out from the cohort (table S1). Further studies 
are needed to clarify this variant’s relationship to neurodevelopmental 
disorders and assess if it is affected differently from other variants 
in vivo. Thus, except for Pro76Leu, the BRPF1 variants are inactive 
in promoting H3K23 acylation by KAT6A.
To establish the in vivo relevance, we analyzed H3K23 propionyl-
ation in cells from individuals with BRPF1 variants. As shown in Fig. 4E, 
this modification decreased in the lymphoblastoid cells (LCLs) prepared 
from the individual harboring the Pro370Ser variant. Moreover, a 
similar albeit less marked deficiency was also observed in the LCLs and 
fibroblasts from the individual with the Arg455* variant (Fig. 4, F and G). 
While BRPF1 variants identified so far are distributed across the entire 
protein (Figs. 3A and 4A) (12, 33), most of the KAT6A and KAT6B 
variants associated with syndromic intellectual disability delete the 
C-terminal part but leave the MYST domain intact (fig. S8, A and C) 
(24–31). Nonsense-mediated mRNA decay does not appear to affect 
transcripts with truncating mutations because most of them are located 
within the last large coding exon (24–30), so many KAT6A or KAT6B 
variants are not expected to alter H3K23 acetylation and propionyl-
ation. Neither was affected in cells with KAT6A or KAT6B variants 
(fig. S8, B and D). Thus, these variants do not impair H3K23 acylation.
A BRPF1 Tyr406His variant was identified in an autistic individual 
(43), but the pathogenicity remains elusive. Tyr406 is highly con-
served from Caenorhabditis elegans to humans (fig. S5), so we ex-
amined the activity of this variant. This variant was well expressed 
(fig. S2F), but it did not copurify well with KAT6A (Fig. 4H, bottom 
two panels). Moreover, the variant complex was also less active than 
the wild type in promoting H3K23 acetylation and propionylation 
by KAT6A (top three panels), supporting the pathogenicity of the 
corresponding variant. These results indicate that BRPF1 dysfunction 
also contributes to autism spectrum disorder (43), further attesting 
to phenotypic variation associated with BRPF1 variants and suggesting 
that they may be broadly associated with neurodevelopmental disorders.
Somatic cancer mutations perturb H3K23 acylation via 
different mechanisms
In addition to germline mutations in individuals with neurodevelopmental 
disorders (Figs. 3A and 4A), somatic BRPF1 mutations have been identi-
fied in medulloblastoma, leukemia, and other types of cancer (Fig. 5A 
and figs. S5 and S9) (23, 44, 45). According to The Cancer Genome 
Atlas datasets, there are 211 cases with 236 BRPF1 mutations, corre-
sponding to ~2% of the 10,240 cancer cases analyzed (fig. S9). Like those 
germline variants identified in individuals with neurodevelopmental 
disorders (Figs. 3A and 4A), these somatic mutations primarily 
comprise two groups: truncating and missense. According to published 
reports (12, 33) and the results in Fig. 4, the truncating somatic mutations 
are expected to inactivate the mutant alleles.
Among the missense mutants, Pro20Leu, Arg29Cys, and Ser36Ile 
alter an N-terminal region with no known function (Fig. 5A and fig. 
S5). This region is absent in the BRPF1 paralogs BRPF2 and BRPF3 
but highly conserved in BRPF1 proteins from Drosophila to humans 
(fig. S5). BLAST (Basic Local Alignment Search Tool) search revealed 
high similarity to a C2H2 zinc finger shared by a group of proteins, 
including the yeast transcription factor Sfp1, so we referred to this 
unique N-terminal region as the Sfp1-like zinc finger (SZ) domain. 
Pro20 is highly conserved among this group of proteins (Fig. 5B) 
and invariant among BRPF1 proteins from Drosophila to humans 
(fig. S5), suggesting the importance of this residue. As shown in fig. S2G 
(lanes 1 to 3), this mutant was much more difficult to express than 
wild-type BRPF1 and also failed to promote expression of ING5 and 
MEAF6. Moreover, this mutant formed a suboptimal tetrameric 
complex with KAT6A, ING5, and MEAF6 (Fig. 5C, bottom two panels). 
The mutant barely stimulated H3K23 acetylation or propionylation 
by KAT6A (Fig. 5C, top three panels, compare lanes 2 and 4). Thus, the 
mutation affects expression, complex formation, and enzymatic activity.
One hotspot mutation is recurrent in six cancer cases and encodes 
Arg66Cys (fig. S9). This residue is part of a putative nuclear local-
ization signal, NLS1 (Fig. 1A and fig. S5), so the mutant may affect 
the function of this NLS. Moreover, three other cancer-associated 
mutants (Arg59His, Arg59Cys, and Gln67Pro) alter Arg59 and Gln67, 
both of which are part of NLS1. We thus analyzed the function of 
this NLS. As shown in Fig. 5D, a fragment (residues 1 to 57) con-
taining the SZ domain of BRPF1 was localized to the nucleus and 
cytoplasm, with some enrichment in the former. Unlike the full-
length BRPF1, coexpression of KAT6A, with or without ING5 and 
MEAF6, did not affect this subcellular distribution. Compared to 
the mutant 1-57, the fragment containing the N-terminal 71 residues 
was more enriched in the nucleus (Fig. 5D), indicating that NLS1 is 
a functional NLS. Thus, Arg66Cys, Arg59His, Arg59Cys, and Gln67Pro 
likely affect the function of NLS1.
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We then verified the activity of Glu253Gly, Leu298Pro, Trp348Arg, 
and Glu369Asp, all of which were identified in medulloblastoma (44). 
As illustrated in Fig. 5A, Glu253 and Leu298 are located at EPC-I 
required for KAT6A/B binding, whereas Trp348 and Glu369 are within 
the PZP domain important for nucleosome binding. Glu253Gly 
promoted expression of ING5 and MEAF6 (fig. S2G, compare lanes 
1 and 2 with lane 4) but formed a suboptimal complex with KAT6A 
(Fig. 5E, bottom two panels, lanes 3 and 4). The interaction with ING5 
and MEAF6 was also compromised (Fig. 5E, bottom, lanes 3 and 4, 
and fig. S2G, lanes 1, 2, and 4). This mutant was less active than 
wild-type BRPF1 in stimulating H3K23 acetylation and propionylation 
by KAT6A (Fig. 5E, top three panels, lanes 2 to 4). Unlike this mutant, 
Leu298Pro, Trp348Arg, and Glu369Asp all formed normal tetrameric 
complexes with KAT6A, ING5, and MEAF6 (Fig. 5E, bottom two 
panels, lanes 5 to 7). However, unlike Glu369Asp, neither Leu298Pro 
nor Trp348Arg stimulated H3K23 acetylation or propionylation by 
KAT6A (Fig. 5E, top three panels, lanes 5 to 7). Thus, Glu253Gly, 
Leu298Pro, and Trp348Arg, but not Glu369Asp, inactivated BRPF1. 
We also analyzed five other cancer-derived missense mutants that 
alter the PZP domain or its C-terminal region (Fig. 5F). Among them, 
Glu303Gln showed a modestly reduced activity in stimulating H3K23 
acylation by KAT6A, whereas Asp344His, Arg347Leu, and the two 
other mutants were comparable to wild-type BRPF1 (Fig. 5F). 
Therefore, cancer-derived somatic BRPF1 mutations exert variable 
effects on H3K23 acylation, reiterating that the impact of each 
mutation needs to be verified experimentally.
Pharmacological manipulation of histone H3K23 acylation
Having established deficient H3K23 acylation caused by BRPF1 
variants from individuals with syndromic intellectual disability 
(Fig. 4) (12, 33) or by somatic mutants from cancer cells (Fig. 5), we 
tested potential means to reverse the deficiency. For this, we first 
investigated whether various HDAC inhibitors up-regulate H3K23 
acylation. For this, we treated HEK293 cells with valproic acid (anti- 
epileptic drug with HDAC inhibitor activity), suberoylanilide 
hydroxamic acid (SAHA) (anti-lymphoma drug, also known as 
vorinostat), -hydroxybutyrate (a common metabolite with HDAC 
inhibitor activity), trichostatin A (TSA; antifungal compound identified 
as the first specific HDAC inhibitor), and butyrate (nonspecific HDAC 
inhibitor and common end product from fermentation of dietary 
fiber by gut microbiota) (46, 47). As shown in Fig. 6A, all these 
inhibitors except -hydroxybutyrate up-regulated H3K23 acetylation 
and propionylation. We then tested Brpf1−/− MEFs. As shown in 
Fig. 6B, all five HDAC inhibitors corrected the deficiency in H3K23 
acetylation and propionylation. We also tested LCLs from the individual 
harboring the Pro370Ser variant. As shown in Fig. 6C, all inhibitors 
except -hydroxybutyrate enhanced H3K23 acetylation and propionyl-
ation. These results suggest potential means to rescue deficient 
H3K23 acylation.
These inhibitors target classical HDACs instead of sirtuins (47). 
In the classical family, HDAC1, HDAC2, and HDAC3 are major 
deacetylases for histone deacetylation (47). Thus, the above results 
suggest the involvement of these three deacetylases in H3K23 deacyla-
tion. Related to this, an HDAC3-specific inhibitor enhanced H3K23 
acetylation in transformed cells (HEK293) and a breast cancer cell 
line (MCF7; Fig. 6D). These results suggest that HDAC3 contributes 
to H3K23 deacylation. Because an HDAC1/2-specific inhibitor also 
up-regulated H3K23 acetylation (48), multiple deacetylases may 
govern H3K23 deacylation.
Propionate treatment enhanced H3K23 propionylation in MEFs 
(Fig. 2D), suggesting another strategy to reverse the deficiency. We thus 
applied the treatment to LCLs derived from an individual with syndromic 
intellectual disability and the Pro370Ser variant (Fig. 4, A and C) 
(12). As shown for MEFs (Fig. 2D), propionate enhanced H3K23 
propionylation in wild-type LCLs cells (Fig. 6E, middle two panels, 
lanes 1 and 3), supporting the view that H3K23 propionylation is 
subject to dynamic regulation by metabolic cues. The treatment also 
enhanced H3K23 propionylation in the patient-derived LCLs (middle 
two panels, lanes 2 and 4). The level was even higher than that in 
wild-type LCLs (compare lanes 1 and 4). Propionate is a common 
short-chain fatty acid (SCFA) produced from microbiotal fermentation 
of dietary fiber in the gut (46), suggesting that dietary modulation 
may be one potential means for modulating histone propionylation.
DISCUSSION
Histone propionylation has recently been identified via mass spectrometry 
(3), but it remains to be established what enzymes catalyze this novel 
acylation in vivo. The results presented here show unequivocally that 
BRPF1-KAT6 complexes are authentic histone H3K23 propionyl-
transferases in vitro and in vivo (Figs. 1, 2, and 6F). For the enzymatic 
assays carried out in vitro (Fig. 1, B and C), we used native and re-
combinant nucleosomes, rather than histone peptides. To establish 
the biological relevance, we analyzed mouse Brpf1 disruption and human 
BRPF1 variants (Figs. 2 to 4). Brpf1 deletion obliterated H3K23 
acylation in mouse embryos and fibroblasts (Fig. 2). BRPF1 variants 
from individuals with neurodevelopmental disorders (Fig. 4) or from 
cancer cells (Fig. 5) impaired BRPF1 in activating KAT6A for H3K23 
propionylation. We have also obtained evidence on potential means 
to manipulate this modification with two known drugs (valproic acid 
and vorinostat) (Fig. 6, A to C) or by treatment with propionate (Fig. 6E). 
Moreover, we demonstrated that propionate and butyrate, two common 
SCFAs produced from microbiota fermentation of dietary fiber (46), 
promote the modification through different mechanisms (Fig. 6G). 
Previous reports established that fly and mammalian KAT6 proteins 
are H3K23 acetyltransferases (10–12). Together with these reports, 
the current study supports that KAT6-BRPF1 complexes are dual- 
functional enzymes for H3K23 acetylation and propionylation.
Histone acetylation is mainly associated with chromatin assembly 
and gene activation (1). Chemically, propionylation is analogous to acetyla-
tion (3), so an important question is what functions this acetylation- 
like acylation has in vivo. We performed coimmunoprecipitation 
(Fig. 2G) and immunofluorescence microscopy (Fig. 2, H and I, and 
fig. S4, A and B) to investigate the association with active chromatin 
labeled by ATAC-See in situ (40). The results indicated that H3K23pr 
is associated with active chromatin. Related to this, H3K23pr fluo-
rescence signals were not localized to heterochromatic nuclear foci 
heavily stained with 4′,6-diamidino-2-phenylindole (Fig. 2, C, H, and I). 
In flies, H3K14pr colocalizes with active genetic loci at the genome- 
wide level (49). Moreover, histone crotonylation is associated with 
transcriptional activation (6, 50). Theoretically, H3K23pr is mutually 
exclusive with other acylation (such as acetylation) of the same residue. 
In future analysis of genome-wide association of H3K23pr, it shall 
be interesting to investigate how this mark is associated with active 
genetic loci and its genome-wide distribution is different from that 
of H3K23ac.
A puzzling question is why BRPF1-KAT6 complexes serve as 
dual-functional enzymes for H3K23 acetylation and propionylation. 
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Although propionylation is chemically similar to acetylation, these 
two modifications are quite different at the metabolic level. One key 
difference lies at distinct acyl-CoA molecules needed as coenzymes. 
As shown in Fig. 6G, acetyl-CoA is downstream from the common 
metabolites pyruvate and acetate, whereas propionyl-CoA is controlled 
by propionate, as well as by metabolites from -oxidation of odd-
chain fatty acids and from metabolism of cholesterol and the amino 
acids Ile, Thr, Val, and Met. Moreover, triheptanoin, a drug in clinical 
trial for fatty acid oxidation disorders, contains three odd-carbon 
fatty acids (Fig. 6G). Activities of BRPF1-KAT6A/B complexes in 
acetylating and propionylating H3K23 in response to acetyl-CoA 
and propionyl-CoA, respectively, confer functional versatility under 
different metabolic conditions. Because some protein domains recognize 
acetylation and other acylation differently (2, 3), H3K23 acetylation 
and propionylation may trigger distinct impact on transcriptomes. 
Because the acetyl-CoA concentration is much higher than propionyl- 
CoA in vivo (51), propionylation may function when and where the 
propionyl-CoA level increases to serve as a regulatory mechanism 
complementary to acetylation (Fig. 6G). The relative concentra-
tion of propionyl-CoA is higher in the liver than the heart, kidney, 
brain, and muscle (51), so the importance of propionylation may 
vary from tissue to tissue. In addition, H3K23pr is more abundant 
in mouse embryos than in cultured cells (fig. S3A), so propionyl-
ation may fluctuate as development progresses. Notably, the 
propionyl-CoA level is elevated in clinical cases of propionic acidemia, 
a recessive genetic disorder that is typically rare but quite prevalent 
in the Greenlandic Inuit population, Amish communities, the 
Middle East, and North Africa (52). The elevated propionic acid 
and propionyl-CoA levels in these cases could lead to hyper-
propionylation (53).
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Fig. 6. Manipulation of histone H3K23 acylation with various compounds. (A) Up-regulated histone H3K23 acylation in HEK293 cells treated with the indicated HDAC 
inhibitor valproate (VPA), vorinostat (SAHA), -hydroxybutyrate (-HB), TSA, or sodium butyrate (SB) for 24 hours. DMSO, dimethyl sulfoxide. (B) Rescue of histone H3K23 
acylation deficiency in Brpf1−/− MEFs by HDAC inhibitors. (C) Rescue of histone H3K23 acylation deficiency in patient-derived LCLs by HDAC inhibitors. For (A) to (C) and 
(E), results with the anti-H3K23cr and anti-H3K23bu antibodies need to be interpreted with caution due to cross-reactivity with H3K23ac and/or H3K23pr (fig. S1B). 
(D) Effect of an HDAC3-specific inhibitor. The indicated cells were treated with the inhibitor RGFP966 for 15 hours. (E) Rescue of histone H3K23 acylation deficiency in 
patient-derived LCLs by propionate. Control and patient-derived LCLs were cultured in a medium supplemented with or without 10 mM sodium propionate for 24 hours. 
For immunoblotting analysis with the anti-H3K23pr antibody, a long exposure (long e.) was also shown (panel 4 from the top). (F) Model explaining how BRPF1 acts 
through KAT6A and KAT6B for controlling histone H3K23 acylation and regulating developmental and pathological processes. HDAC inhibitors such as VPA, SAHA, TSA, 
and butyrate up-regulate acylation. These compounds offer therapeutic potential for the related diseases. Short-chain fatty acid (SCFAs) and other metabolites regulate 
acyl-CoA levels, thereby controlling H3K23 acylation. (G) Expanded version of the green box in (F) highlighting how various metabolites may differentially regulate acetyla-
tion and propionylation. For simplicity, only pyruvate and acetate are illustrated for events upstream from acetyl-CoA, a central player downstream from diverse meta-
bolic pathways. On the basis of relative concentrations of acetyl-CoA and propionyl-CoA in vivo, we propose that acetylation plays a major role, whereas propionylation 
complements acetylation.
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Acetate, propionate, and butyrate are the most common SCFAs 
produced from fermentation of dietary fiber by gut microbiota (46). 
These SCFAs are of direct importance to physiology and health of 
the host. Two signaling functions have been assigned to these SCFAs. 
All of them can function as G protein–coupled receptor agonists, 
whereas butyrate, but not acetylate or propionate, also acts as an 
HDAC inhibitor (46). As expected from its activity as an HDAC 
inhibitor, butyrate promoted H3K23 acetylation and propionylation 
(Fig. 6, A to C). Related to this, phenylbutyrate is used to treat urea 
cycle disorders. Propionate treatment stimulated H3K23 propionylation 
but not acetylation in MEFs (Fig. 2D) and patient cells (Fig. 6F). 
This is likely through propionyl-CoA (Fig. 6G). These results identify a 
third signaling function for SCFAs and link H3K23 propionylation 
to fermentation of dietary fiber by the intestinal microbiota.
As for pathological relevance, KAT6A and KAT6B are rearranged 
or amplified in leukemia and other cancers (23, 54). Leukemia- 
associated chromosomal translocations tend to leave the MYST 
domains of KAT6A and KAT6B intact (Fig. 1A) (23, 38). KAT6A, 
KAT6B, and BRPF1 are also frequently amplified in some cancer 
types (fig. S9) (23). In these cases, unwanted acylation may be the 
culprit, so BRPF1 and KAT6 inhibitors (Fig. 6F) may be of thera-
peutic value due to their activity to mitigate elevated acylation. On 
the other hand, inactivating BRPF1 mutations are associated with 
medulloblastoma and other cancer types (Fig. 5) (44, 45). In these 
cases, up-regulation of H3K23 acylation by deacetylase inhibitors 
(Fig. 6) may be of therapeutic value. Thus, specific mutation-based 
strategies are needed for different genomic contexts.
KAT6A or KAT6B variants have been identified in ~300 individuals 
with neurodevelopmental disorders characteristic of intellectual 
disability (24–32). BRPF1 variants are present in 40 cases of syndromic 
intellectual disability (Figs. 3 and 4) (12, 33–36) and one individual 
with autism (43). As reported for H3K23 acetylation (12, 33), these 
variants impaired BRPF1 in activating KAT6A (and perhaps also 
KAT6B) for H3K23 propionylation (Fig. 4). Notably, neither H3K23 
acetylation nor propionylation was compromised in five patient-derived 
cell lines with KAT6A or KAT6B variants (fig. S8, B and D), which 
is expected because they contain intact MYST domains (fig. S8, 
A and C). A few KAT6A or KAT6B variants alter their MYST domains 
(31, 32) and may thus affect acylation. The drugs valproate and 
vorinostat rescued acylation defects in cultured cells with mouse 
Brpf1 (or human BRPF1) mutations (Fig. 6, B and C). Moreover, 
butyrate and propionate corrected acylation deficiency (Fig. 6, C and E). 
They are major end products from fermentation of dietary fiber by 
gut microbiota (46), while propionate is a nutrient supplement 
(marketed as Propicum).
One interesting issue is in regard to structural and functional 
differences between KAT6A and KAT6B (Fig. 1A). As two paralogs, 
they are highly homologous to each other at the sequence level (23) 
and also display similar properties in vitro, in terms of complex for-
mation with BRPF1 and histone H3 acylation. The MYST domain 
of KAT6A or KAT6B had H3K23 propionyltransferase activity in vitro 
(Fig. 1, C and E). However, they display functional differences in vivo, 
in part due to their distinct expression patterns. In addition, their 
regulatory mechanisms may be different in vivo. Their knockout mice 
display distinct phenotypes (23), and patients with KAT6A or 
KAT6B variants exhibit different clinical features (24–32).
In summary, this study identifies BRPF1-KAT6 complexes as 
H3K23 propionyltransferases and links histone propionylation 
deficiency to developmental disorders and cancer. We propose that 
compared to acetylation, propionylation serves a complementary 
regulatory mechanism (Fig. 6, F and G). This study thus not only 
suggests targeted therapeutic strategies for medical conditions with 
germline (or somatic) BRPF1, KAT6A, or KAT6B variants but also 
sheds light on the metabolic disorder propionic acidemia and 
propionate-based nutrient supplements.
MATERIALS AND METHODS
Human individuals
Families were consented for clinical studies approved by the CHU 
Sainte-Justine Institutional Review Board (IRB) (Montreal, Quebec, 
Canada). At the Autism and Developmental Medicine Institute at 
Geisinger, patients are offered participation in an IRB-approved protocol 
that allows the use and publication of clinically obtained data (including 
genetic test results) to be used for research purposes. For publication 
of the photos in Fig. 3 and fig. S4C, informed written consent was 
obtained specifically.
Exome and Sanger sequencing
Clinical exome sequencing was carried out as described (12, 33). 
Exome sequencing was carried out at a clinical genetic testing laboratory 
for individual P7, but parental samples were unavailable for testing.
Mice and animal study approval
Mice strains were maintained in the Comparative Medicine and 
Animal Resources Centre of McGill University, Montreal, Quebec, 
Canada. All procedures related to mouse work were performed accord-
ing to an animal use protocol approved by the McGill University 
Animal Care Committee.
Brpf1f/f mice were maintained in C57BL/6J genetic background, 
in which the conditional Brpf1f allele contains two LoxP sites flanking 
exons 4 to 6 (39, 55, 56). Breeding with Brpf1f/f mice and UBC-Cre/ERT2 
strain (The Jackson Laboratory, 007001) generated Brpf1f/+;ER-Cre mice, 
which were further intercrossed to yield Brpf1f/f;ER-Cre embryos for 
MEF isolation (39). For epiblast-specific knockouts, Brpf1f/f mice were 
crossed with the Meox2-Cre strain (The Jackson Laboratory, 003755). 
Brpf1 knockout embryos (E10.5) were prepared from intercross of 
Brpf1f/+;Meox2-Cre mice, as previously described (12). The Kat6af/f 
mice line was generated in a mixed C57BL/6J-CD1 genetic background 
(12). The Kat6af  allele contains two LoxP sites flanking the second 
coding exon. Crossing this mice line with the EIIa-Cre stain (The 
Jackson Laboratory, 003724) yielded Kat6af/+;EIIa-Cre mice, which 
were further intercrossed to generate Kat6a knockout embryos and 
MEFs (57). Knockout efficiency was verified by genomic polymerase 
chain reaction (PCR) and/or reverse transcription quantitative real- 
time PCR (57).
Cell lines and MEFs
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium 
(Gibco, 11995-073) supplemented with 10% heat-inactivated fetal 
bovine serum (Gibco, A3160702), penicillin (100 U/ml), and strep-
tomycin (100 g/ml). Both fibroblasts and LCLs including controls 
and those from patients with the Pro370Ser and Arg455* variants 
were prepared as described (12). Breast cancer MCF7 cells were cultured 
in the above medium. MEFs were prepared and cultured as previously 
described (12). MEFs from tamoxifen-inducible Brpf1ff;ER-Cre embryos 
were used to obtain Brpf1-null MEFs after treatment with 0.25 M 
4-hydroxytamoxifen (Sigma-Aldrich, T176) for 3 days in vitro (39). 
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Kat6a-null MEFs were prepared from Kat6af/f;EIIa-Cre embryos as 
described (57).
Fluorescence microscopy
For analysis of subcellular localization, expression plasmids for EGFP 
(enhanced green fluorescent protein)–BRPF1 and its mutants were 
transiently transfected into HEK293 cells with or without expression 
vectors for KAT6A, ING5, and MEAF6 as specified in Fig. 5D. 
About 16 hours after transfection, live green fluorescence signals were 
examined under a fluorescence microscope, and images were captured 
for further processing as described (18).
Mutagenesis and acetyltransferase complex reconstitution
All expression constructs were engineered on derivatives of the 
mammalian expression vector pcDNA3.1 (Invitrogen). Site-directed 
mutagenesis to generate expression vectors for HA-tagged BRPF1 
variants corresponding to the variants identified in individuals with 
syndromic intellectual disability was carried out via PCR with Pfu 
Ultra High-fidelity DNA Polymerase AD (Agilent, 600385), followed 
by Dpn I digestion. After transformation into DH5, plasmids were 
isolated from the resulting colonies for restriction digestion and 
further verification of the variants by Sanger DNA sequencing.
For BRPF1-KAT6 complex reconstitution in cells, an expression 
plasmid for FLAG-tagged KAT6A, its fragment or a KAT6B frag-
ment was transfected into HEK293 cells along with the expression 
vectors for HA-tagged BRPF1, ING5, and MEAF6 as described (18, 21). 
About 48 hours after transfection, cells were washed twice with 
phosphate-buffered saline (PBS), and soluble protein extracts were 
prepared in buffer K for affinity purification on anti-FLAG M2 agarose 
(Sigma-Aldrich, A2220), as previously described (18, 21). After ex-
tensive washing three times with buffer K containing 0.6 M KCl and 
once with buffer K, the FLAG peptide (Sigma-Aldrich, F3290) was 
added to buffer K to elute bound proteins for immunoblotting analysis 
with anti-FLAG and anti-HA antibodies or for acetyltransferase 
activity determination. Acetylation of HeLa oligonucleosomes was 
performed as described (18, 21). Because of no basal acylation signals 
detected, recombinant mononucleosomes were used for most of the 
assays presented here (except for Figs. 1B and 4B).
Histone acylation assays
The assays were performed as previously reported (18, 21). Briefly, 
reconstituted KAT6 complexes were incubated with 0.2 to 1 g of 
nucleosomes and 0.1 mM acetyl-CoA (Sigma-Aldrich, A2056), 
propionyl-CoA (Sigma-Aldrich, P5397), crotonyl-CoA (Sigma-Aldrich, 
28007), or butyryl-CoA (Sigma-Aldrich, B1508) at 37°C for 1 hour. 
HeLa oligonucleosomes were purified as previously described 
(21), where recombinant mononucleosomes were purchased from 
EpiCypher (16-0009). Reactions were terminated by addition of a 3× 
reducing SDS sample buffer for separation by SDS–polyacrylamide 
gel electrophoresis (PAGE) (15%) and transferred to 0.22-m nitro-
cellulose membrane (Pall Laboratory, 66485) and subsequent immuno-
blotting analysis to detect histone H3 or its acylation with site-specific 
antibodies as described below. The KAT6 complexes in the acylation 
reactions were verified by immunoblotting with anti-FLAG (Sigma- 
Aldrich, F3165) and anti-HA (BioLegend, 901515) antibodies.
Immunoblotting analysis
For assessment of endogenous histone acylation, cells and embryos 
were lysed in the radioimmunoprecipitation assay (RIPA) buffer 
[150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM tris-HCl (pH 8.0), and protease inhibitor mixture] for immuno-
blotting. Histone acylation was analyzed by immunoblotting with 
anti-H3 (Abcam, ab1791; 1:100,000), anti-H3K9ac (Abcam, ab10812; 
1:1000), anti-H3K18ac (EMD Millipore, 07-354; 1:1000), anti-H3K23ac 
(EMD Millipore, 07-355; 1:10,000), anti-H3K23pr (PTM Biolabs, 
PTM-205; 1:1000), anti-H3K23cr (PTM Biolabs, PTM-519; 1:1000), 
anti-H3K23bu (PTM Biolabs, PTM-307; 1:1000), anti-H3K23me3 
(Active Motif, 61499; 1:1000), anti-H3K14ac (EMD Millipore, 07-353; 
1:1000), anti-H3K14pr (PTM Biolabs, PTM-211; 1:1000), anti-H3K14cr 
(PTM Biolabs, PTM-535; 1:1000), anti-H3K14hib (PTM Biolabs, PTM-881; 
1:1000), anti-propionyllysine (PTM Biolabs, PTM-201; 1:1000), anti- 
crotonyllysine (PTM Biolabs, PTM-502; 1:1000), and anti-succinyllysine 
(PTM Biolabs, PTM-402; 1:1000) antibodies in 5% nonfat milk or 
bovine serum albumin in the TBST (Tris-buffered saline with Tween 20) 
buffer for overnight at 4°C. Goat anti-Rabbit IgG (H+L)-HRP (Thermo 
Fisher Scientific, 65-6120) and Goat anti-Mouse IgG (H+L)-HRP 
(Thermo Fisher Scientific, 62-6520) were used as the secondary anti-
bodies at a dilution of 1:5000 for blotting for 1 hour at room tem-
perature. After extensive washing four times with the TBST buffer 
(7 min each), blots were developed with the Pierce ECL Western Blot-
ting Substrate (Thermo Fisher Scientific, 32109).
Coimmunoprecipitation
Coimmunoprecipitation was carried out as described (21). Briefly, 
25 g of extracts from wild-type or Brpf1−/− MEFs (E13.5) was pre-
incubated with 5 g of antibody in the NP-40 buffer [50 mM tris-HCl 
(pH 8.0), 50 mM NaCl, 1% NP-40, 50 mM NaF, and protease inhibitor 
cocktail] with overnight rotation at 4°C. Immunoprecipitation was 
then performed by incubating each mixture with 25 l of Dynabeads 
Protein G (Invitrogen, 10003D) with rotation for 45 min at 4°C. After 
washing four times with 0.5 ml of PBS containing 0.02% Tween 20 
and protease inhibitor cocktail, the Dynabeads were resuspended in 
the reducing SDS sample buffer and boiled for 5 min. The super-
natant was used for SDS-PAGE and immunoblotting analysis with 
the indicated antibodies.
Pharmacological treatment
Cells were seeded so that they would reach at ~90% confluency on 
the following day. After one wash with PBS, cells were treated with 
the medium supplemented with the vehicle solvent, sodium propionate 
(Sigma-Aldrich, P5436), sodium valproate (Sigma-Aldrich, P4543), SAHA 
(Sigma-Aldrich, SML0061), -hydroxybutyrate (Sigma-Aldrich, H6501), 
TSA (Sigma-Aldrich, T8552), sodium butyrate (Sigma-Aldrich, B5887), 
or HDAC3 inhibitor RGFP966 (Selleckchem, S7229) for 24 hours. Cells 
were washed with PBS and lysed in the RIPA buffer (Thermo Fisher 
Scientific, 89900) to prepare soluble protein extracts or in the 
Triton extraction buffer (PBS containing 0.5% Triton X-100, 2 mM 
phenylmethylsulfonyl fluoride, 0.02% NaN3, and protease inhibitors) 
to prepare protein extracts. Extracts were prepared in buffer K and 
further analyzed by immunoblotting with various antibodies as 
described above.
ATAC-See and immunofluorescence microscopy
The ATAC-See procedure was modified from a published report on 
cells (58) to obtain more reliable results for cultured cells and extend 
the application to paraffinized tissue sections. The isopropyl--d- 
thiogalactopyranoside (IPTG)–inducible expression vector pTXB1-
Tn5 was obtained from Addgene (60240). Hyperactive Tn5 was 
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bacterially expressed and affinity-purified according to a published 
procedure (59). On the basis of SDS-PAGE and Colloidal Coomassie 
blue staining, purified Tn5 protein was adjusted to ~1 mg/ml. The 
Tn5 adaptor ATTO633-Tn5ME/Tn5MErev was assembled from the 
ATTO-633 N-labeled oligo (/5ATTO633N/TCGTCGGCAGCGT-
CAGATGTGTATAAGAGACAG) and the Tn5MErev oligo (/5Phos/
CTGTCTCTTATACACATCT) (58). The Tn5 transposome was 
assembled from 2 l of Tn5 protein, 0.2 l of the Tn5 adaptor ATTO633- 
Tn5ME/Tn5MErev (12.5 M/each oligo), 2 l of 50% glycerol, and 
0.8 l of H2O. After incubation at room temperature for 1 hour, the 
assembled Tn5 transposome was stored shortly at 4°C for transpo-
sition reactions.
For ATAC-See, MEFs were grown on round coverslips in wells 
of a 12-well plate. At 80 to 90% confluency, cells were fixed with 1% 
formaldehyde (Sigma-Aldrich, F8775) for 10 min at room temperature. 
After fixation, the cells were permeabilized with the modified lysis 
buffer [10 mM tris-Cl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, and 
0.2% Triton X-100] for 10 min at room temperature. Paraffinized 
control and Kat6a−/−;EIIa-Cre embryo sections were deparaffinized 
for antigen retrieval as previously described (39, 55, 56) and permea-
bilized with the modified lysis buffer for 10 min at room temperature. 
After permeabilization, coverslips or embryo sections were rinsed 
twice in PBS.
For transposition reactions, the assembled Tn5 transposome was 
mixed with 25 l of 2× tagmentation buffer [33 mM tris-acetate (pH 7.8), 
66 mM potassium acetate, 11 mM magnesium acetate, and 16% 
N,N-dimethylformamide] and 20 l of H2O. The mixture was added 
onto coverslips or embryo sections for incubation at 37°C for 60 min. 
After transposition reactions, coverslips were washed thrice with the 
washing buffer (0.01% SDS and 50 mM EDTA in PBS) at 55°C. For 
paraffinized tissue sections, a modified washing buffer (0.5% SDS, 
100 mM EDTA, and 0.25 M NaCl in PBS) was used to reduce auto-
fluorescence background. After ATAC-See, immunofluorescence 
microscopy using antibodies specific to histone or its modified forms 
was carried out as described (39, 55, 56). Alexa Fluor 488–conjugated 
anti-rabbit immunoglobulin G (IgG) (Invitrogen, A-11034) and Alexa 
Fluor 488–conjugated anti-mouse IgG (Invitrogen, A-11001) were 
used as the secondary antibodies.
Sequence alignment
The sequence similarity with Sfp1 was initially noticed during BLAST 
search using the C2H2 zinc finger region of BRPF1 as bait, with a 
P value of 3 × 10−4. GenBank accession numbers used for the align-
ment in Fig. 5B are P55201 (BRPF1), NP_001286155 (Br140), 
NP_013507 (Sfp1), NP_651853 (CG12054), XP_006715719 (JAZF1), 
and XP_011519688 (ZF609). Asterisks denote Cys and His residues 
that may be involved in chelating zinc for zinc finger formation; 
His47 may replace His44 for zinc chelating. The known or potential 
DNA-recognizing residues at three key positions (60) are highlighted 
in bold (Fig. 5B). The sequence alignment was generated with the 
ClustIW module of a MacVector software package (version 11.10.2).
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